InterMune Achieves $10M Roche Milestone

InterMune, Inc. has successfully completed large-scale synthesis and delivery to Roche of an API for a hepatitis C virus (HCV) drug candidate ITMN-191, currently in a Phase Ia trial. The milestone triggered a $10 million payment to InterMune as part of the companies’ HCV collaboration.

“InterMune has successfully executed key steps in the manufacture of a very sophisticated protease inhibitor molecule and transferred the materials to Roche for future studies,” said Lawrence M. Blatt, Ph.D., chief scientific officer of InterMune. “We’re pleased to have completed these crucial manufacturing-related activities and that our HCV clinical development program that is partnered with Roche is off to an excellent start.”